The Procter Gamble Company

Kelly Lee Schmeichel

Kurt Franklin Trombley

Jay Robert Morosey, Jr

Diane Danheiser Powers

Craig Andrew Hawkins

Thomas Alfred Inglin

Angela Jane Deutsch

Rosa Manuela Leon Alonso

Eduardo De Abreu Mangione

Niranjan Ramji

Susan Elaine Criss

Elaine Rose Costeines

Douglas William Gledhill

Jayant Khanolkar

Karla Mishell Sanchez

Isabelle Lafosse-Marin

Karen Lai-Ting Chan

Juan Esteban Velasquez

Amy Violet Trejo

Gregory Allen Penner

Erin Swigart

Adam Michael Pitz

Spencer Christopher Rupard

Isabelle La Fosse-Marin

Isabelle LaFosse-Marin

Isabella La Fosse-Marin

Jay Robert Morosey

Jr Morosey Jay Robert

Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives.

Compositions and methods useful for treatment of respiratory illness

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

Aptamers for personal health care applications

Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.

A child-resistant blister package. The package has a top face, a bottom face, and a periphery. The package also has a protection layer with a top face, a bottom face and a periphery; a blister layer with one or more cavities; and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along substantially the entire periphery of the package. The blister package can also contain a tear resistant layer.

Child-resistant blister package

A portable blister card including a front side and a back side opposite the front side. The front side includes a face having a width, a right side edge, a left side edge, a top edge, and an outer periphery. In addition, the front side includes a first blister and a second blister extending outwardly at the face and a primary manufacturer indicia area comprising a manufacturer indicator visible on the front side. The first blister contains a first unit dose and the second blister contains a second unit dose, wherein the first and second unit doses are different. The back side includes regulatory information that remains on the back side when each unit dose is removed from each blister through the back side of the card.

Blister cards promoting intuitive dosing

A daily blister card housing a unit dose includes a back side and a front side opposite the back side. The front side includes a manufacturer indicator visible on the front side. A face has an outer periphery and a total planar area bounded by the outer periphery. One or more blisters extend outwardly at the face that contains at least three unit doses that are visible from outside the one or more blisters. Each of the one or more blisters includes a shoulder contacting a cavity backing surface and a projected cavity area bounded by the shoulder that is projected onto the cavity backing surface. A total projected cavity area of the one or more blisters is no more than about 45 percent of the total planar area bounded by the outer periphery.

A conveniently portable daily blister card including a front side and a back side opposite the front side. The front side includes a face having a width, a right side edge, a left side edge, a top edge, and an outer periphery. In addition, the front side includes at least three blisters extending outwardly at the face and a primary manufacturer indicia area. Each blister contains a unit dose. The back side includes regulatory information that remains on the back side when a unit dose is removed from a blister through the back side of the card.

A blister card with a back side and a front side opposite the back side. The front side has a plurality of blisters and each blister contains a unit dose and each unit dose contains an active. Each blister card contains from about 12 hours to about 24 hours of unit doses according to the dosage instructions. The actives can be the same or different.

A daily blister card housing a unit dose includes a back side and a front side opposite the back side. The front side includes a manufacturer indicator visible on the front side. A face has an outer periphery and a total planar area bounded by the outer periphery. One or more blisters extend outwardly at the face that contain at least three unit doses that are visible from outside the one or more blisters. Each of the one or more blisters includes a shoulder contacting a cavity backing surface and a projected cavity area bounded by the shoulder that is projected onto the cavity backing surface. A total projected cavity area of the one or more blisters is no more than about 45 percent of the total planar area bounded by the outer periphery.

Growing community of inventors

Cincinnati, OH, United States of America

Kelly Lee Schmeichel